Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.

Zou, Xinhua; Xu, Qingyu; You, Ran; Yin, Guowen

Zou, Xinhua; Xu, Qingyu; You, Ran; Yin, Guowen.

Affiliation

Zou X; Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing City, China.
Xu Q; Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing City, China.
You R; Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing City, China.
Yin G; Department of Tumor Interventional Therapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing City, China.

Cancer Med ; 12(10): 11315-11333, 2023 05.

Article de En | MEDLINE | ID: mdl-36951443

Sujet(s)
Mots clés

hepatocellular carcinoma; inflammatory cytokines; lenvatinib; programmed cell death-1 inhibitor; transarterial chemoembolization

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thrombose / Chimioembolisation thérapeutique / Carcinome hépatocellulaire / Tumeurs du foie Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Cancer Med Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google